Literature DB >> 3584392

Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy.

D L Andress, N A Maloney, J W Coburn, D B Endres, D J Sherrard.   

Abstract

The bone histology in patients with chronic renal failure and aluminum-related bone disease does not always show the excess accumulation of unmineralized osteoid (matrix) characteristic of osteomalacia. Frequently, bone aluminum accumulation is associated with normal or reduced amounts of unmineralized osteoid and low bone formation and is referred to as aplastic bone disease. In this study, we compared static and dynamic bone histomorphometric parameters and plasma PTH and aluminum levels in 12 patients with osteomalacia and 18 patients with aplastic bone disease who had been receiving dialysis for the same duration to determine if the difference in osteoid accumulation in these 2 lesions might be explained by differences in aluminum accumulation or PTH levels. The stainable bone surface aluminum level was significantly higher in the patients with osteomalacia compared to that in the group with aplastic bone [61 +/- 5% (+/- SEM) vs. 43 +/- 4%; P less than 0.02]. The rates of bone apposition and bone formation were lower in the group with osteomalacia (P less than 0.01). Plasma amino-terminal PTH was not significantly different in the 2 groups. The increment in plasma aluminum levels after a single infusion of deferoxamine was higher in the osteomalacic group than in the aplastic group, suggesting that the patients with osteomalacia accumulated more total body chelatable aluminum than did those with aplastic bone disease during a comparable length of time on dialysis. We conclude that the excess unmineralized osteoid in aluminum-related osteomalacia results from the high rate of total body aluminum accumulation, which directly causes uncoupling of matrix mineralization and matrix production, independent of PTH levels. Patients with aplastic bone disease who have accumulated lesser amounts of total body aluminum fail to develop excess unmineralized osteoid because production and mineralization of matrix are more closely coupled than in the osteomalacic lesion, despite a decline in osteoblast numbers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3584392     DOI: 10.1210/jcem-65-1-11

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Does iron affect osteoblast function? Studies in vitro and in patients with chronic liver disease.

Authors:  T Diamond; R Pojer; D Stiel; A Alfrey; S Posen
Journal:  Calcif Tissue Int       Date:  1991-06       Impact factor: 4.333

Review 2.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Aluminum Intoxication in Chronic Kidney Disease.

Authors:  Rodrigo Bueno de Oliveira; Fellype Carvalho Barreto; Lucas Acatauassu Nunes; Melani Ribeiro Custódio
Journal:  J Bras Nefrol       Date:  2021-12-03

4.  A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats.

Authors:  Ellen Neven; Tineke M De Schutter; Geert Dams; Kristina Gundlach; Sonja Steppan; Janine Büchel; Jutta Passlick-Deetjen; Patrick C D'Haese; Geert J Behets
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.